Propofol for the treatment of migraines in the ED might be on the horizon.
This will possibly be a new practice in emergency medicine, although it has been known for some time. Propofol, when given at procedural sedation doses, seems to miraculously terminate migraines refractory to usual treatment. Patients awake with minimal to no headache and may be discharged from the ED much quicker than traditional treatment with possibly less side effects. The proposed mechanism of action is described in below papers, but in short, propofol seems to "reboot" the brain and terminate the migraine.
What is the evidence?
What is the evidence?
It all started with a paper by Krusz et al in Headache 2000 in the late 1990s at a headache clinic using propofol for procedural sedation during epidural blocks.
Who:
- 77 patients with headache severity ≥7/10 on VAS failing outpatient oral regimens
Intervention:
- Non-blinded 20-30 mg of IVP propofol every 3-5 minutes until symptom resolution not to exceed 1 hour
Results:
- Average reduction in headache severity = 95.4% at 30 minutes
- 82% had total abolition of migraines and associated symptoms
- 18% had a VAS-pain decrease of 50-90%
- 3 of 77 patients had return of headache the following day
- Average dose of propofol 110 mg (~1-1.5 mg/kg for average size adult)
- No adverse events
Then in 2012, Soleimanpour et al published in BMC Neurology, a prospective randomized double-blind trial conducted in Iran.
Who:
- 90 adult ED patients presenting with a migraine
Intervention:
- Propofol 10 mg IVP every 5-10 minutes (maximum of 80 mg) versus dexamethasone 0.15 mg/kg (max 16 mg) IVP
Results:
- Propofol performed statistically better as measured by VAS pain reduction at 5, 10, 20, 30, and 45 minute marks
- Propofol group adverse events: 2 patients desat to 89% resolving with O2 administration
Don't forget that kids get migraines too! A 2012 retrospective case-control review by Sheridan et al in Pediatric Emergency Care from a pediatric ED studied kids with migraines who received propofol compared to standard treatment.
Who:
- 7 pediatric patients with migraines receiving sub-anesthetic doses of propofol were compared to those with usual abortive therapy (NSAIDs + prochloroperazine + diphenhydramine)
Intervention:
- Average of 1.71 mg/kg of propofol total given as 10-50 mg IVP doses
Results:
- Propofol was significantly better at decreasing VAS pain (80% vs 60%)
- No difference in length-of-stay after medications
- No difference in re-visits after 24 hours
- No adverse events
If you do decide to use propofol for migraines, here are some recommendations:
- Consider for patients failing usual rescue treatments
- Follow your ED's protocol for procedural sedation
- Administer propofol as 10-20 mg IVP every 3-4 minutes up to 1 mg/kg
- Aim to have a lightly sedated patient - the goal is not for the EtCO2 to disappear
- Consider one-dose of dexamethasone 10 mg IV/PO prior to discharge to prevent recurrence (Colman et al in BMJ & Huang et al in Eur J Neuro)
Conclusion
There might be some benefit to the milky goodness of propofol for intractable migraines in the ED, but adequate trials are currently lacking.
Zlatan Coralic, PharmD (@ZEDPharm) Assistant Clinical Professor, UCSF Emergency Department Clinical Pharmacist |
Image 1
References
- Krusz JC, Scott V, Belanger J. Intravenous propofol: Unique effectiveness in treating intractable migraine. Headache. 2000Mar;40(3):224-30. PMID 10759925
- Soleimanpour H, Ghafouri RR, Taheraghdam A,Aghamohammadi D, Negargar S, Golzari SE, et al. Effectiveness of intravenous dexamethasone versus propofol for pain relief in the migraine headache: Aprospective double blind randomized clinical trial. BMC Neurol. 2012 Sep29;12:114,2377-12-114. PMID 23020264
- Sheridan DC, Spiro DM, Nguyen T, Koch TK,Meckler GD. Low-dose propofol for the abortive treatment of pediatric migraine in the emergency department. Pediatr Emerg Care. 2012 Dec;28(12):1293-6. PMID 23187986
- Colman I, Friedman BW, Brown MD, Innes GD, Grafstein E, Roberts TE, et al. Parenteral dexamethasone for acute severe migraine headache: Meta-analysis of randomised controlled trials for preventing recurrence. BMJ. 2008 Jun 14;336(7657):1359-61. PMID 18541610
- Huang Y, Cai X, Song X, Tang H, Huang Y, Xie S, et al. Steroids for preventing recurrence of acute severe migraine headaches: A meta-analysis. Eur J Neurol. 2013 Apr 11. PMID 23577697







































Javier Ben















.png)

























.jpg)





